Data from the DUO-E trial support the FDA approval of durvalumab/chemotherapy for those with primary advanced or recurrent dMMR endometrial cancer.
Approval Alert | Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
2
Single-Agent PD-1 Blockade Therapy Improves Responses in Desmoplastic Melanoma
3
64Cu-SAR-bisPSMA PET Detects More Prostate Cancer Lesions vs SOC
4
Real-World Data From IMS: Promising Results in Relapsed/Refractory Multiple Myeloma
5
